SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
Biotech Beach
The Day In Review: Immunicon Corporation Rises On AstraZeneca PLC Deal
August 7, 2006
 · 
1 min read
Business
The Day In Review: Biogen Idec, Inc. (Massachusetts) Invests In ALS Compound
August 4, 2006
 · 
1 min read
Drug Development
The Day In Review: Pozen, Inc. Inks Pain Deal With AstraZeneca PLC
August 3, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Crucell N.V. And Astellas Pharma Inc. Abandon Drugs
July 18, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Sanofi-Aventis (France) In-Licenses Japanese Cancer Drug
July 5, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Cambridge Antibody Technology Group PLC Acquisition Keeps Biotech In The Black
May 15, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Feds Invest $1 Billion In Domestic Flu Vaccines
May 4, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Biotechs Update Hepatitis C News
May 1, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Abraxis BioScience, Inc. Signs Deal With AstraZeneca PLC
April 27, 2006
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
June 29, 2026
 · 
14 min read
Press Releases
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
June 26, 2026
 · 
10 min read
Press Releases
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
 · 
7 min read
Press Releases
AstraZeneca Joins ZERO Prostate Cancer’s Historic ‘Blitz the Barriers’ Initiative as a Founding Partner
June 15, 2026
 · 
3 min read
Press Releases
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 14, 2026
 · 
19 min read
Press Releases
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 8, 2026
 · 
7 min read
Press Releases
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
June 3, 2026
 · 
4 min read
Press Releases
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 1, 2026
 · 
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 29, 2026
 · 
19 min read
Press Releases
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 24, 2026
 · 
19 min read
Load More